About the Company
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 14, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2025 Financial and Business Results Conference ...
Protalix BioTherapeutics Reports Strong Q2 2025 Results
Protalix Biotherapeutics ( ($PLX) ) has released its Q2 earnings. Here is a breakdown of the information Protalix Biotherapeutics presented to its ...
Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call ...
Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce ...
CARMIEL, Israel, Feb. 23, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and ...
Protalix Submits BLA for Fabry Disease Candidate PRX-102
Protalix BioTherapeutics, Inc. PLX and its partner Chiesi Global Rare Diseases, a unit of Chiesi, announced that they have submitted a biologics license application ("BLA") to the FDA for ...
Protalix BioTherapeutics Provides Update on Complete Response Letter ...
Protalix designed PRX–102 to potentially address the continued unmet clinical need in Fabry patients. About Protalix BioTherapeutics, Inc.
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To ...
Protalix was founded by Yoseph Shaaltiel in 1993. Protalix BioTherapeutics, Inc. (NYSE:PLX) showcases an impressive upside potential of 1,422%, indicating a highly optimistic outlook from analysts.
Protalix Biotherapeutics Inc. | BioWorld
Protalix Biotherapeutics Inc. saw shares dip after releasing initial top-line data from an interim analysis of the phase III Balance clinical trial of pegunigalsidase alfa (PRX-102) to treat Fabry ...
Protalix BioTherapeutics (PLX) CEO Dror Bashan on Q1 2021 Results ...
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan On Q2 2021 Results - Earnings Call Transcript Aug. 16, 2021 2:27 PM ET Protalix BioTherapeutics, Inc. (PLX) Stock PLX SA Transcripts ...
Protalix Finalizes Accelerated Approval Pathway for PRX-102
Protalix BioTherapeutics, Inc. PLX and its Italian partner Chiesi Farmaceutici S.p.A. announced that they have successfully completed a type B pre-Biologics License Application (“BLA”) meeting ...
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
On July 4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, The One Big Beautiful Bill Act, which includes significant corporate tax changes, including a ...
Similar Companies
Loading the latest forecasts...